IDIA Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Idorsia Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2.74 |
| 52 Week High | CHF 6.90 |
| 52 Week Low | CHF 1.29 |
| Beta | 1.07 |
| 11 Month Change | 33.33% |
| 3 Month Change | 44.42% |
| 1 Year Change | -58.74% |
| 33 Year Change | -87.74% |
| 5 Year Change | -87.26% |
| Change since IPO | -79.90% |
Recent News & Updates
Recent updates
Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
May 30
Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
May 26Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
May 01Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts
Apr 05Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
Mar 10Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Mar 08There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise
Dec 28The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts
Jul 27Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable
Jun 14We Think Idorsia (VTX:IDIA) Has A Fair Chunk Of Debt
Apr 13What You Need To Know About The Idorsia Ltd (VTX:IDIA) Analyst Downgrade Today
Feb 02Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?
Dec 15Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?
Sep 01Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
May 11Is Idorsia (VTX:IDIA) Using Debt Sensibly?
May 03Analysts' Revenue Estimates For Idorsia Ltd (VTX:IDIA) Are Surging Higher
Feb 21Shareholder Returns
| IDIA | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 20.5% | -5.8% | -1.0% |
| 1Y | -58.7% | 79.9% | 2.8% |
Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned 79.9% over the past year.
Return vs Market: IDIA underperformed the Swiss Market which returned 2.8% over the past year.
Price Volatility
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.1% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: IDIA's share price has been volatile over the past 3 months.
Volatility Over Time: IDIA's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Jean-Paul Clozel | www.idorsia.com |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.
Idorsia Ltd Fundamentals Summary
| IDIA fundamental statistics | |
|---|---|
| Market cap | CHF 494.17m |
| Earnings (TTM) | CHF 28.66m |
| Revenue (TTM) | CHF 127.84m |
17.2x
P/E Ratio3.9x
P/S RatioIs IDIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDIA income statement (TTM) | |
|---|---|
| Revenue | CHF 127.84m |
| Cost of Revenue | CHF 299.86m |
| Gross Profit | -CHF 172.02m |
| Other Expenses | -CHF 200.68m |
| Earnings | CHF 28.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 29, 2024
| Earnings per share (EPS) | 0.16 |
| Gross Margin | -134.56% |
| Net Profit Margin | 22.42% |
| Debt/Equity Ratio | -108.5% |
How did IDIA perform over the long term?
See historical performance and comparison